Biocon Limited · NSE:BIOCON

Biocon — Q1 FY26 Earnings Presentation

16 slides from Biocon's earnings presentation, Aug 8, 2025

1. Slide 1: Cover letter to stock exchanges

   Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com BIO/SECL/TG/2025-26/71 August 08, 2025 To, To, The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Cor

2. Slide 2: Biocon Limited Q1 FY26 Earnings Call

   Biocon Limited Q1 FY26 Earnings Call 08 - A U G U S T - 2 0 2 5

3. Slide 3: Safe Harbor Statement

   Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s

4. Slide 4: Chairperson Opening Remarks

   Chairperson Opening Remarks

5. Slide 5: Opening Remarks: Q1 FY26 Performance Overview

   Opening Remarks: Q1 FY26 Performance Overview Equity Fundraise: Successfully raised ₹4,500 crores through QIP, first equity fundraise since IPO in 2004 Funds will be used to increase stake in Biocon Biologics & provide an exit to private equity investors Product Launches & Approvals: Received US FDA

6. Slide 6: Q1 FY26 Financial Highlights

   Q1 FY26 Financial Highlights

7. Slide 7: Financial Highlights – Q1 FY26

   Financial Highlights – Q1 FY26 In ₹ Cr Q1 FY26 Q1 FY25 Q4 FY25 YoY%3 QoQ% Generics 697 659 1,048 6 (33) Biosimilars 2,458 2,083 2,463 18 0 CRDMO# 875 790 1,018 11 (14) Revenue from Operations 3,942 3,433 4,417 15 (11) Total Revenue 4,022 4,5671 4,454 15 (10) Core EBITDA2 1,003 903 1,363 11 (26) % Ma

8. Slide 8: Generics

   Generics

9. Slide 9: Biocon Generics: Q1 FY26 Business Performance update

   Biocon Generics: Q1 FY26 Business Performance update Q1 Q1 Q4 In ₹ Cr YoY% QoQ% FY26 FY25 FY25 Q1 growth supported by new product introductions - Liraglutide in the EU, Lenalidomide & Dasatinib in the US as well as higher API volume. Segment 697 659 1,048 6 (33) Revenue Received India approval for L

10. Slide 10: Biosimilars

    Biosimilars

11. Slide 11: Biocon Biologics: Q1 FY26 Business Performance update

    Biocon Biologics: Q1 FY26 Business Performance update Focus in FY26 • Scaling commercialised products • Deepening presence in key markets Q1 Q1 Q4 • Preparing for future launches to drive sustainable and profitable growth In ₹ Cr YoY% QoQ% FY26 FY25 FY25 North America Highlights Segment • Received U

12. Slide 12: CRDMO

    CRDMO

13. Slide 13: CRDMO: Q1 FY26 Business Performance update

    CRDMO: Q1 FY26 Business Performance update Q1 Q1 Q4 In ₹ Cr YoY% QoQ% Positive start to FY26 with growth in Q1 driven by research services FY26 FY25 FY25 segment with pilot programs transitioning to long-term contracts Segment 875 790 1,018 11 (14) EBITDA growth of 19% with a 25% margin Revenue Capa

14. Slide 14: Concluding Remarks

    Use as Separator Concluding Remarks

15. Slide 15: Concluding Remarks: Q1 FY26

    Concluding Remarks: Q1 FY26 All three businesses segments are seeing accelerated growth QIP has strengthened the balance sheet and enhanced financial flexibility. Will enable Biocon to increase its shareholding in Biocon Biologics, reduce interest burden and improve leverage ratios Aligning our busi

16. Slide 16: Q&A

    $ Biocon REACH EXPANDING ACCESS PROPELLING GROWTH Q&A

Biocon — Q1 FY26 Earnings Presentation on 6ix